梁晓杰;王亮;
LIANG Xiaojie;WANG Liang;First Clinical Medical College, Southern Medical University;Department of Hematology, Beijing Tongren Hospital, Capital Medical University;

• 1:南方医科大学第一临床医学院
• 2:首都医科大学附属北京同仁医院血液内科

摘要(Abstract)：

原发性眼内淋巴瘤(primary intraocular lymphoma, PIOL)是一种罕见的淋巴细胞恶性肿瘤。目前,PIOL的诊断仍面临一定挑战,组织细胞病理活检是诊断的金标准,基因检测、细胞因子检测、流式细胞分析技术等多种检测方法联合应用可提高其诊断准确率。PIOL的标准化治疗方案尚未达成共识,局部放疗、玻璃体腔内化疗和大剂量全身化疗是控制疾病的有效手段。鉴于PIOL预后差、易复发的特点,早期诊断和治疗非常重要。
Primary intraocular lymphoma(PIOL) is a rare non-Hodgkin lymphoma and classified as a special subtype of primary central nervous system lymphoma(PCNSL). At present, the diagnosis of PIOL still faces some challenges because it can masquerade as uveitis, behcet disease and so on. Its histopathologic biopsy remains the standard approach to diagnose PIOL. Gene detection, flow cytometry analysis, and determination of cytokine levels can increase the diagnostic accuracy of PIOL. Currently, there are no standard therapies for PIOL,although local radiotherapy, intravitreal chemotherapy and high-dose systemic chemotherapy are effective to control it. However, the prognosis of PIOL is poor because it is prone to local recurrence and developing into PCNSL.Therefore, early diagnosis and treatment are very important for the prognosis of PIOL.

关键词(KeyWords)： 原发性眼内淋巴瘤;诊断;治疗
primary intraocular lymphoma;diagnosis;treatment

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81873450)~~

作者(Authors): 梁晓杰;王亮;
LIANG Xiaojie;WANG Liang;First Clinical Medical College, Southern Medical University;Department of Hematology, Beijing Tongren Hospital, Capital Medical University;

参考文献(References)：

• [1]Tang LJ,Gu CL,Zhang P.Intraocular lymphoma[J].Int J Ophthalmol,2017,10:1301-1307．
• [2]Chaput F,Amer R,Baglivo E,et al.Intraocular T-cell Lymphoma:Clinical Presentation,Diagnosis,Treatment,and Outcome[J].Ocul Immunol Inflamm,2017,25:639-648．
• [3]Bohn JP,Willenbacher W,Haas G,et al.Pomalidomide in primary intraocular lymphoma[J].Leuk Lymphoma,2019,60:1584-1586．
• [4]Cho BJ,Yu HG.Risk factors for intraocular involvement in patients with primary central nervous system lymphoma[J].J Neurooncol,2014,120:523-529．
• [5]Mochizuki M,Singh AD.Epidemiology and clinical features of intraocular lymphoma[J].Ocul Immunol Inflamm,2009,17:69-72．
• [6]Goto H,Mochizuki M,Yamaki K,et al.Epidemiological survey of intraocular inflammation in Japan[J].Jpn JOphthalmol,2007,51:41-44．
• [7]Sagoo MS,Mehta H,Swampillai AJ,et al.Primary intraocular lymphoma[J].Surv Ophthalmol,2014,59:503-516．
• [8]Chan CC,Rubenstein JL,Coupland SE,et al.Primary vitreoretinal lymphoma:a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J].Oncologist,2011,16:1589-1599．
• [9]Chan CC.Primary intraocular lymphoma:clinical features,diagnosis,and treatment[J].Clin Lymphoma,2003,4:30-31．
• [10]Kimura K,Usui Y,Goto H.Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J].Jpn J Ophthalmol,2012,56:383-389．
• [11]Mashayekhi A,Shukla SY,Shields JA,et al.Choroidal lymphoma:clinical features and association with systemic lymphoma[J].Ophthalmology,2014,121:342-351．
• [12]Kiratli H,Ag(in A,Büyükeren B,et al.Primary Diffuse Large B-Cell Lymphoma of the Ciliary Body[J].Ocul Immunol Inflamm,2019,27:407-409．
• [13]Chan CC,Sen HN.Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J].Discov Med,2013,15:93-100．
• [14]Casady M,Faia L,Nazemzadeh M,et al.Fundus autofluorescence patterns in primary intraocular lymphoma[J].Retina,2014,34:366-372．
• [15]Majumder PD,Raghothaman N,Kharel R,et al.Retinal necrosis as the initial presentation of primary intraocular lymphoma[J].Nepal J Ophthalmol,2017,9:83-86．
• [16]Grimm SA,McCannel CA,Omuro AM,et al.Primary CNS lymphoma with intraocular involvement:International PCNSL Collaborative Group Report[J].Neurology,2008,71:1355-1360．
• [17]Hwang CS,Yeh S,Bergstrom CS.Diagnostic vitrectomy for primary intraocular lymphoma:when,why,how?[J].Int Ophthalmol Clin,2014,54:155-171．
• [18]Fend F,Ferreri AJ,Coupland SE.How we diagnose and treat vitreoretinal lymphoma[J].Br J Haematol,2016,173:680-692．
• [19]Konstantinidis L,Angi M,Coupland SE,et al.Primary B-cell lymphoma of the ciliary body with 360°(‘ring’-like)growth pattern[J].Eye (Lond),2014,28:355-356．
• [20]Hoang-Xuan K,Bessell E,Bromberg J,et al.Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients:guidelines from the European Association for NeuroOncology[J].Lancet Oncol,2015,16:e322-e332．
• [21]Keino H,Okada AA,Watanabe T,et al.Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma[J].Ocul Immunol Inflamm,2016,24:268-273．
• [22]Fardeau C,Lee CP,Merle-Béral H,et al.Retinal fluorescein,indocyanine green angiography,and optic coherence tomography in non-Hodgkin primary intraocular lymphoma[J].Am J Ophthalmol,2009,147:886-894．
• [23]Davis JL,Viciana AL,Ruiz P.Diagnosis of intraocular lymphoma by flow cytometry[J].Am J Ophthalmol,1997,124:362-372．
• [24]Missotten T,Tielemans D,Bromberg JE,et al.Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma[J].Ophthalmology,2013,120:991-996．
• [25]Hiemcke-Jiwa LS,Ten Dam-van Loon NH,Leguit RJ,et al.Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction[J].JAMAOphthalmol,2018,136:1098-1104．
• [26]Tuo J,Shen D,Yang HH,et al.Distinct microRNA-155expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis[J].Am J Ophthalmol,2014,157:728-734．
• [27]Ohta K,Sano K,Imai H,et al.Cytokine and molecular analyses of intraocular lymphoma[J].Ocul Immunol Inflamm,2009,17:142-147．
• [28]Cassoux N,Giron A,Bodaghi B,et al.IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma[J].Invest Ophthalmol Vis Sci,2007,48:3253-3259．
• [29]Wolf LA,Reed GF,Buggage RR,et al.Vitreous cytokine levels[J].Ophthalmology,2003,110:1671-1672．
• [30]Kim MM,Dabaja BS,Medeiros J,et al.Survival Outcomes of Primary Intraocular Lymphoma:A Single-institution Experience[J].Am J Clin Oncol,2016,39:109-113．
• [31]Levasseur SD,Wittenberg LA,White VA.Vitreoretinal lymphoma:a 20-year review of incidence,clinical and cytologic features,treatment,and outcomes[J].JAMAOphthalmol,2013,131:50-55．
• [32]Milgrom SA,Cheah CY,Pinnix CC,et al.Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma[J].Leuk Lymphoma,2016,57:2612-2618．
• [33]Teckie S,Yahalom J.Primary intraocular lymphoma:treatment outcomes with ocular radiation therapy alone[J].Leuk Lymphoma,2014,55:795-801．
• [34]Ma WL,Hou HA,Hsu YJ,et al.Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[J].Ann Hematol,2016,95:593-601．
• [35]Tempescul A,Pradier O,Marianowski-Cochard C,et al.Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma[J].Ann Hematol,2011,90:1117-1118．
• [36]Frenkel S,Hendler K,Siegal T,et al.Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience[J].Br J Ophthalmol,2008,92:383-388．
• [37]Kitzmann AS,Pulido JS,Mohney BG,et al.Intraocular use of rituximab[J].Eye (Lond),2007,21:1524-1527．
• [38]Kim H,Csaky KG,Chan CC,et al.The pharmacok-inetics of rituximab following an intravitreal injection[J].Exp Eye Res,2006,82:760-766．
• [39]Ghesquieres H,Chevrier M,Laadhari M,et al.Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma:a multicenter prospective‘proof of concept’phaseⅡstudy of the French Oculo-Cerebral lymphoma (LOC)Network and the Lymphoma Study Association (LYSA)[J].Ann Oncol,2019,30:621-628．
• [40]Lionakis MS,Dunleavy K,Roschewski M,et al.Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J].Cancer Cell,2017,31:833-843．
• [41]Wang L,Guan W,Peng X.Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma:Report of 3 Cases[J].Front Oncol,2021,11:676792．
• [42]Goodman A,Patel SP,Kurzrock R.PD-1-PD-L1 immunecheckpoint blockade in B-cell lymphomas[J].Nat Rev Clin Oncol,2017,14:203-220．
• [43]Nayak L,Iwamoto FM,LaCasce A,et al.PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J].Blood,2017,129:3071-3073．
• [44]Schorb E,Finke J,Ihorst G,et al.Age-adjusted highdose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients[J].BMCCancer,2019,19:287．
• [45]Ferreri AJ,Blay JY,Reni M,et al.Prognostic scoring system for primary CNS lymphomas:the International Extranodal Lymphoma Study Group experience[J].J Clin Oncol,2003,21:266-272.